Trials / Unknown
UnknownNCT05905354
Clinical Study of HPV Therapeutic DNA Vaccine (NWRD08) in Patients With Cervical HPV16 and/or HPV18 Positive
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Newish Technology (Beijing) Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is an open-label exploratory clinical study. The main objective is to explore the immunogenicity of HPV therapeutic DNA vaccine NWRD08.
Detailed description
The main objective is to explore the immunogenicity of HPV therapeutic DNA vaccine NWRD08.The secondary objective was to observe the safety of NWRD08 in cervical patients who were positive for HPV16 and/or HPV18, and to initially explore the efficacy of NWRD08.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NWRD08 | Subjects in dose group 1 and 2 were intramuscularly injected with NWRD08 at week 0, week 4 and week 12 by electric pulse gene delivery instrument, respectively. Subjects in dose group 3 and 4 were intramuscularly injected NWRD08 at week 0, week 2, week 4 and week 12 by electric pulse gene delivery instrument, respectively. |
Timeline
- Start date
- 2022-03-07
- Primary completion
- 2024-06-30
- Completion
- 2024-12-31
- First posted
- 2023-06-15
- Last updated
- 2023-06-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05905354. Inclusion in this directory is not an endorsement.